AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (AMPK and mGPDH)

AMP-activated protein kinase (AMPK) and mitochondrial glycerophosphate dehydrogenase (mGPDH) are two distinct enzymes that serve as critical regulators of cellular energy homeostasis and metabolic flux. AMPK is a heterotrimeric kinase that acts as a metabolic master switch, sensing changes in the cellular energy charge (AMP:ATP ratio) to activate catabolic pathways and inhibit anabolic processes [1][2]. Mitochondrial glycerophosphate dehydrogenase is an enzyme located on the inner mitochondrial membrane that facilitates the glycerol-3-phosphate shuttle, a key mechanism for maintaining the redox balance required for hepatic gluconeogenesis [3]. These two proteins are frequently discussed together because they are the primary molecular targets of metformin, the first-line pharmacological treatment for type 2 diabetes [4]. Metformin-mediated inhibition of mGPDH leads to an altered cytosolic redox state that suppresses glucose production in the liver, while its activation of AMPK enhances peripheral insulin sensitivity and reduces lipid accumulation [5][6]. Beyond diabetes, these targets are of significant interest in research regarding metabolic syndrome, obesity, and potential anti-cancer therapies [7].

Other names

AMPKmGPDHGPD2Glycerol-3-phosphate dehydrogenase 2PRKAA1PRKAA2Mitochondrial glycerol-3-phosphate dehydrogenase

Metformin inhibits mitochondrial glycerophosphate dehydrogenase (mGPDH), which increases the cytosolic NADH/NAD+ ratio and suppresses hepatic gluconeogenesis from lactate and glycerol; it also activates AMP-activated protein kinase (AMPK) indirectly by increasing the AMP:ATP ratio, leading to inhibited lipid synthesis and improved insulin sensitivity [3][4][5].